ReviewFrontiers in cardiovascular medicine2026
Heart-liver co-management: epidemiology, mechanisms, and novel therapeutic approaches for metabolic dysfunction-associated steatotic liver disease and coronary artery disease.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and coronary artery disease (CAD) are interconnected global health epidemics that substantially contribute to worldwide morbidity and mortality. We aimed to provide a systematic overview of the epidemiological links and shared pathophysiological mechanisms between MASLD and CAD, evaluate emerging therapeutic strategies with dual benefits, and advocate for an integrated "dual-heart-liver" management model. Methods: We synthesize current evidence to examine the epidemiological link between MASLD and CAD and their shared pathophysiological mechanisms, including endothelial dysfunction, chronic inflammation, metabolic imbalance, insulin resistance, and genetic associations. We also discuss the roles of genetic predisposition, lifestyle modification, and combination therapies in improving patient outcomes. Furthermore, recent advances in pharmacotherapy-such as resmetirom, GLP-1 receptor agonists, SGLT2 inhibitors, FGF21 analogues, PCSK9 inhibitors, and PPAR agonists-are evaluated for their dual benefits on hepatic and cardiovascular health. Results: Epidemiological studies confirm a bidirectional, mutually reinforcing relationship between MASLD and CAD, which are linked through multiple pathophysiological pathways. In terms of treatment, novel pharmacotherapies-such as resmetirom, GLP-1 receptor agonists, SGLT2 inhibitors, FGF21 analogues, PCSK9 inhibitors, and PPAR agonists-show considerable potential for conferring concurrent hepatic and cardiovascular benefits. Furthermore, combination therapies also play important roles in optimizing patient outcomes. Conclusions: This review calls for a paradigm shift toward an integrated "dual-heart-liver" management model, emphasizing the need for systematic cardiovascular risk assessment in MASLD patients and the implementation of collaborative care strategies to improve long-term prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.